2021 Update on Metastatic Triple Negative Breast Cancer Treatment - Metastatic Breast Cancer Trial Talk

Research News


Triple-negative breast cancer (TNBC) is a breast cancer subtype that tests negative for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors 2 (HER2). Since TNBC tumors lack known targets for drug development, the treatment options have been mostly limited to chemotherapy. 

Recently, however, new treatment options have become available, including immunotherapy, PARP inhibitors and the antibody drug conjugate Trodelvy (sacituzumab govitecan). Additionally, there are other types of drugs and regimens currently being studied in clinical trials, including drugs targeting the PI3K/AKT/mTOR pathway, the androgen receptor pathway, and regimens that combine PARP inhibitors, immune checkpoint inhibitors and other types of drugs.

See below for information on current treatment options and drugs currently being studied in clinical trials. 

Overview of Approved and Investigational Drugs for TNBC
Clinical Trials for People with Metastatic TNBC

Last Modified on March 22, 2021



for past articles or specific information.